NEUROGENE INC (NGNE)

US64135M1053 - Common Stock

66  +19.93 (+43.26%)

After market: 68.8599 +2.86 (+4.33%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

NEUROGENE INC

NASDAQ:NGNE (11/4/2024, 8:26:12 PM)

After market: 68.8599 +2.86 (+4.33%)

66

+19.93 (+43.26%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month103.08%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap857.34M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

NGNE Daily chart

Company Profile

Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company is headquartered in New York City, New York and currently employs 91 full-time employees. The company went IPO on 2014-03-07. The Company, through its proprietary transgene regulation technology, Expression Attenuation via Construct Tuning (EXACT), is building a product portfolio of genetic medicines for rare neurological diseases with high unmet needs not otherwise addressable by conventional gene therapy. Its clinical-stage program, NGN-401, utilize the EXACT platform, which is under development for the treatment of Rett syndrome, a disease with a patient population that has a significant unmet need, and that ultimately progresses to substantial neurological and physical impairment and premature death. NGN-401 is being evaluated in pediatric female patients with Rett syndrome in a Phase 1/2 open-label, multi-center clinical trial that assesses the safety, tolerability, and efficacy of two doses of NGN-401 delivered using a one-time intracerebral ventricular (ICV) procedure. The company is also developing NGN-101 for the treatment of CLN5 Batten disease.

Company Info

NEUROGENE INC

535 W 24Th Street, 5Th Floor

New York City NEW YORK

P: 18772375020

Employees: 91

Website: https://www.neurogene.com/

NGNE News

ChartMill News Image13 hours ago - ChartmillKeep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.

Monday's session: top gainers and losers

ChartMill News Image16 hours ago - ChartmillWhat's going on in today's session

Let's have a look at the top gainers and losers in the middle of the day of today's session.

ChartMill News Image18 hours ago - ChartmillThese stocks are gapping in today's session

Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps.

ChartMill News Image20 hours ago - ChartmillThese stocks are moving in today's pre-market session

Stay updated with the stocks that are on the move in Monday's pre-market session.

News Image21 hours ago - Neurogene Inc.Neurogene Announces Oversubscribed $200 Million Private Placement
News Image15 days ago - NeurogeneNeurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

NGNE Twits

Here you can normally see the latest stock twits on NGNE, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example